Michael J Keating Selected Research

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

1/2023	A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
12/2011	The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.
8/2010	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
6/2006	Activity of alemtuzumab in patients with CD52-positive acute leukemia.
4/2006	Richter's transformation in chronic lymphocytic leukemia.
4/2006	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
9/2004	Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
6/2004	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael J Keating Research Topics

Disease

168	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 08/2023 - 02/2002
62	Neoplasms (Cancer) 11/2023 - 02/2002
30	Leukemia 01/2021 - 05/2002
13	Lymphoma (Lymphomas) 06/2017 - 02/2002
12	Residual Neoplasm 11/2019 - 01/2003
12	Infections 06/2017 - 05/2002
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2019 - 11/2002
11	Disease Progression 05/2017 - 12/2003
10	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 05/2006
8	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2023 - 06/2004
6	Chromosome Aberrations (Chromosome Abnormalities) 01/2018 - 08/2002
6	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 09/2011 - 04/2002
6	B-Cell Lymphoma (Lymphoma, B Cell) 05/2011 - 02/2002
5	Mitochondrial Diseases (Mitochondrial Disease) 12/2017 - 04/2009
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2015 - 11/2002
5	Lymphocytosis 07/2015 - 09/2011
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2012 - 05/2002
5	Prolymphocytic Leukemia 01/2003 - 02/2002
4	Diarrhea 01/2020 - 10/2014
4	Cytopenia 01/2016 - 05/2006
4	Trisomy (Trisomies) 07/2015 - 08/2002
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2013 - 04/2002
4	Philadelphia Chromosome 08/2010 - 05/2002
3	Hypoxia (Hypoxemia) 09/2011 - 01/2005
3	Anemia 01/2009 - 10/2002
3	Hairy Cell Leukemia 06/2006 - 11/2002
3	Multiple Myeloma 01/2006 - 11/2002
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/2003 - 02/2002
2	Nausea 01/2020 - 09/2003
2	Vomiting 01/2020 - 09/2003
2	Virus Diseases (Viral Diseases) 06/2017 - 09/2006
2	Epstein-Barr Virus Infections 06/2017 - 05/2006
2	Atrial Fibrillation 11/2016 - 12/2014
2	Colitis 01/2016 - 01/2015

Drug/Important Bio-Agent (IBA)

41	fludarabineIBA 11/2019 - 04/2002
41	Rituximab (Mabthera)FDA Link 11/2019 - 02/2002
25	ibrutinibIBA 01/2020 - 02/2012
23	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2019 - 02/2002
17	Monoclonal AntibodiesIBA 10/2015 - 02/2002
16	Proteins (Proteins, Gene)FDA Link 04/2019 - 01/2003
15	Alemtuzumab (Campath)FDA Link 08/2011 - 05/2002
12	Lenalidomide (CC 5013)FDA Link 01/2019 - 04/2008
12	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2018 - 06/2003
11	MicroRNAs (MicroRNA)IBA 08/2023 - 04/2009
11	Agammaglobulinaemia Tyrosine KinaseIBA 01/2020 - 02/2012
9	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2018 - 04/2002
8	Antineoplastic Agents (Antineoplastics)IBA 09/2011 - 05/2003
7	Phosphotransferases (Kinase)IBA 01/2021 - 02/2012
7	Messenger RNA (mRNA)IBA 12/2011 - 06/2005
6	NucleosidesIBA 01/2023 - 12/2003
6	idelalisibIBA 03/2017 - 09/2011
6	RNA (Ribonucleic Acid)IBA 12/2011 - 06/2005
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2003
5	Alkylating AgentsIBA 03/2017 - 02/2002
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017 - 09/2003
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2015 - 04/2002
5	Adenosine Triphosphate (ATP)IBA 10/2012 - 01/2005
5	Immunoglobulins (Immunoglobulin)IBA 04/2009 - 12/2003
5	AntigensIBA 05/2008 - 02/2002
5	Mitochondrial DNA (mtDNA)IBA 12/2006 - 09/2003
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2014 - 12/2006
4	CytokinesIBA 12/2013 - 08/2002
4	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2013 - 05/2009
4	DNA (Deoxyribonucleic Acid)IBA 04/2011 - 12/2003
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2009 - 09/2004
4	triphosphoric acid (triphosphate)IBA 03/2008 - 12/2003
3	ProdrugsIBA 01/2023 - 02/2002
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 05/2009
3	venetoclaxIBA 01/2022 - 08/2015
3	EnzymesIBA 01/2017 - 11/2002
3	ChemokinesIBA 12/2013 - 03/2009
3	Hemoglobins (Hemoglobin)IBA 01/2009 - 10/2002
3	OligonucleotidesIBA 01/2009 - 08/2005
3	Clofarabine (Clolar)FDA Link 07/2006 - 12/2003
3	Cladribine FDA LinkGeneric 07/2006 - 01/2003
3	Imatinib Mesylate (Gleevec)FDA Link 06/2004 - 05/2002
2	nelarabine (506U78)FDA Link 01/2023 - 03/2008
2	Apoptosis Regulatory ProteinsIBA 01/2022 - 01/2021
2	ofatumumab FDA Link 01/2020 - 01/2016
2	Nonesterified Fatty Acids (NEFA)IBA 11/2018 - 01/2016
2	Tyrosine (L-Tyrosine)FDA Link 11/2017 - 04/2010
2	Antigen Receptors (Antigen Receptor)IBA 10/2017 - 06/2011
2	Bendamustine Hydrochloride FDA Link 03/2017 - 06/2014
2	Glutathione (Reduced Glutathione)IBA 01/2017 - 11/2016
2	Serine (L-Serine)FDA Link 01/2017 - 04/2010
2	AntioxidantsIBA 01/2017 - 03/2004
2	carfilzomibIBA 09/2016 - 01/2015
2	Ligases (Synthetase)IBA 01/2016 - 04/2009
2	LipidsIBA 01/2016 - 05/2015
2	Immunoglobulin M (IgM)IBA 01/2016 - 04/2005
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2015 - 01/2015
2	Proteasome InhibitorsIBA 01/2015 - 04/2009

Therapy/Procedure

61	Therapeutics 11/2023 - 05/2002
17	Drug Therapy (Chemotherapy) 06/2017 - 11/2002
6	Stem Cell Transplantation 05/2017 - 01/2004
5	Aftercare (After-Treatment) 01/2016 - 05/2002
4	Salvage Therapy 01/2018 - 04/2008
4	Immunotherapy 07/2011 - 01/2003
3	Transplantation 01/2019 - 05/2007
2	Immunomodulation 12/2019 - 01/2004